Cancer BiologybioRxivPreprint
A reversible SRC-relayed COX2-inflammatory program drives therapeutic resistance in BRAF(V600E) colorectal tumors
A. Ruiz-Saenz, C. E. Atreya, C. Wang…·J.-P. Coppe
This study identifies a SRC-relayed COX2-inflammatory program that drives resistance to BRAF/MEK/EGFR therapies in BRAFV600E colorectal tumors and shows that co-targeting COX2 improves therapeutic outcomes.
DOI 10.1101/2022.10.20.512885